AR130727A1 - Compuestos tricíclicos y sus usos - Google Patents

Compuestos tricíclicos y sus usos

Info

Publication number
AR130727A1
AR130727A1 ARP230102707A ARP230102707A AR130727A1 AR 130727 A1 AR130727 A1 AR 130727A1 AR P230102707 A ARP230102707 A AR P230102707A AR P230102707 A ARP230102707 A AR P230102707A AR 130727 A1 AR130727 A1 AR 130727A1
Authority
AR
Argentina
Prior art keywords
compounds
tricyclic compounds
combinations
compound
formula
Prior art date
Application number
ARP230102707A
Other languages
English (en)
Inventor
Vincent Bordas
Markus Furegati
Jacques Hamon
Juergen Hans Hinrichs
- Hong Ziyue Hermann
Fabio Lima
Fatma Limam
Henrik Moebitz
Sandro Nocito
Niko Schmiedeberg
Joseph Schoepfer
Ross Strang
Frdric Zecri
Huangchao Yu
Yong Zhang
Xinkan Yang
Sisi Zhang
Wei Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR130727A1 publication Critical patent/AR130727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (1), en donde R¹, R², R³, x, R⁴, R⁵, y, R, M, W, L, V, T, Y, J, K y A han sido definidos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como productos químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos a elaboración de los compuestos de la invención.
ARP230102707A 2022-10-12 2023-10-10 Compuestos tricíclicos y sus usos AR130727A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022124865 2022-10-12
EP22208192 2022-11-17
US202363494033P 2023-04-04 2023-04-04
CN2023108913 2023-07-24

Publications (1)

Publication Number Publication Date
AR130727A1 true AR130727A1 (es) 2025-01-15

Family

ID=88315575

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102707A AR130727A1 (es) 2022-10-12 2023-10-10 Compuestos tricíclicos y sus usos

Country Status (17)

Country Link
US (1) US20240245694A1 (es)
EP (1) EP4601746A1 (es)
JP (1) JP2025536259A (es)
KR (1) KR20250079023A (es)
CN (1) CN120077048A (es)
AR (1) AR130727A1 (es)
AU (1) AU2023361889A1 (es)
CL (1) CL2025001072A1 (es)
CR (1) CR20250187A (es)
DO (1) DOP2025000087A (es)
IL (1) IL319660A (es)
JO (1) JOP20250072A1 (es)
MX (1) MX2025004220A (es)
PE (1) PE20251323A1 (es)
TW (1) TW202417450A (es)
UY (1) UY40470A (es)
WO (1) WO2024079623A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024286830A1 (en) 2023-06-08 2025-12-04 Nimbus Wadjet, Inc. Wrn inhibitors
EP4755890A1 (en) * 2023-08-01 2026-06-10 Haisco Pharmaceutical Group Co., Ltd. Oxo-tricyclic derivative and pharmaceutical use thereof
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
AU2024410908A1 (en) 2023-12-29 2026-07-16 Suzhou Genhouse Bio Co., Ltd. Fused ring compound, pharmaceutical composition containing same and use thereof
TW202539684A (zh) * 2024-01-15 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 一種三唑並嘧啶類衍生物、其製備方法與應用
WO2025162478A1 (en) * 2024-02-04 2025-08-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
TW202547484A (zh) 2024-04-10 2025-12-16 瑞士商諾華公司 藥物組合及其用途
WO2025218781A1 (en) * 2024-04-19 2025-10-23 Insilico Medicine Ip Limited Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
WO2025223396A1 (en) * 2024-04-22 2025-10-30 3H Pharmaceuticals Co., Ltd. Fused tricyclic compounds and methods of use thereof
WO2025232693A1 (en) * 2024-05-08 2025-11-13 Nuphase Therapeutics (Shanghai) Limited., Co. Novel compounds, compositions comprising the same and uses thereof
WO2025237361A1 (zh) * 2024-05-16 2025-11-20 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025237389A1 (zh) * 2024-05-17 2025-11-20 成都微芯药业有限公司 三环wrn抑制剂、其制备方法及其应用
WO2025242186A1 (zh) * 2024-05-24 2025-11-27 浙江海正药业股份有限公司 氮杂三环类衍生物及其制备方法和用途
WO2025247335A1 (en) * 2024-05-30 2025-12-04 Allorion Therapeutics Inc Compounds and use thereof as wrn inhibitors
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
CN121426817A (zh) * 2024-07-10 2026-01-30 广州科恩泰生物医药科技有限公司 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2008027990A1 (en) * 2006-08-29 2008-03-06 Trustees Of Boston University Therapeutic methods using wrn binding molecules
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2022093820A1 (en) * 2020-10-28 2022-05-05 Genentech, Inc. Substituted morpholine compounds
AR125966A1 (es) * 2021-05-26 2023-08-30 Novartis Ag Nuevos compuestos bicíclicos y sus usos
WO2024105610A1 (en) * 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
US20260184716A1 (en) * 2022-11-23 2026-07-02 Novartis Ag Solid forms of a fused pyridine for the treamtent of cancer
US20250368646A1 (en) * 2024-05-28 2025-12-04 Nimbus Wadjet, Inc. Tricyclic fused wrn inhibitors

Also Published As

Publication number Publication date
KR20250079023A (ko) 2025-06-04
EP4601746A1 (en) 2025-08-20
CN120077048A (zh) 2025-05-30
WO2024079623A1 (en) 2024-04-18
TW202417450A (zh) 2024-05-01
MX2025004220A (es) 2025-05-02
PE20251323A1 (es) 2025-05-16
JOP20250072A1 (ar) 2025-04-10
CR20250187A (es) 2025-06-04
UY40470A (es) 2024-05-15
DOP2025000087A (es) 2025-06-15
CL2025001072A1 (es) 2025-08-01
IL319660A (en) 2025-05-01
US20240245694A1 (en) 2024-07-25
JP2025536259A (ja) 2025-11-05
AU2023361889A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
DOP2025000087A (es) Compuestos tricíclicos y sus usos
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
CL2021003202A1 (es) Compuestos de pirrolidina
CO2025005872A2 (es) Compuestos tricíclicos y sus usos
AR116283A1 (es) Inhibidores del sarcómero cardíaco
CO2024001367A2 (es) Compuestos antivirales
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
AR118515A1 (es) Compuestos y su uso en el tratamiento del cáncer
AR134204A1 (es) Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
CO2021017202A2 (es) Compuestos tricíclicos
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
AR134040A1 (es) Moduladores de mrgprx2 y métodos de tratamiento relacionados
AR128693A1 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR130303A1 (es) Compuestos de pirazolilsulfonamida y su uso terapéutico
AR114263A1 (es) Compuestos terapéuticos y métodos para utilizarlos
AR124982A1 (es) Macrociclos y sus usos
AR132445A1 (es) Moduladores de nk3 y usos de los mismos
AR132539A1 (es) Compuestos de pirazol 3h-imidazo(4,5-b)piridina y usos de los mismos
AR120654A1 (es) Macrociclos para uso en el tratamiento de enfermedades
AR134206A1 (es) Degradantes y usos de los mismos
AR134553A1 (es) Compuestos y composiciones antivirales y usos de los mismos